Efficacy of Alpha Lipoic Acid Supplementation In Chemotherapy-Induced Peripheral Neuropathy

Abstract

A B S T R A C TBackground. Chemotherapy-induced peripheral neuropathy is a side effect ofseveral chemotherapy drugs and a significant cause of chronic pain in cancerpatients, which affects patients' long-term quality of life. The neurotoxicchemotherapy agents most reported to cause neuropathic pains are platinum andtaxane. This study aimed to determine the efficacy of alpha-lipoic acidsupplementation in chemotherapy patients. Methods. This study used arandomized, double-blind clinical trial in the oncology haematology clinic in theDepartment of Internal Medicine at Mohammad Hoesin General Hospital Palembangfrom November 2018 to July 2019. Samples were taken from patients who met theinclusion criteria and signed informed consent forms to join the study. This studyused SPSS version 22.0 for Windows to analyze the data.Results. This researchstudied 30 subjects who were divided into alpha lipoic acid groups and placebogroups with 15 samples each. The alpha-lipoic acid group showed a significantdecline in the Toronto Clinical Scoring System (TCSS) after treatment (p = 0.000)compared to the placebo group (p = 0.164). Conclusions. Treatment with a 600 mgsingle dose each day of alpha-lipoic acid for 12 weeks effectively improved patientscondition significantly.